摘要
目的探究贝伐珠单抗靶向治疗卵巢癌患者对肿瘤标志物的影响。方法选取72例卵巢癌患者,采用分层抽样法将患者分为对照组与研究组,每组36例。对照组患者使用常规化疗方案进行化疗,研究组患者在对照组基础上联合贝伐珠单抗靶向治疗。对比两组临床疗效。结果治疗前,两组糖类抗原125(CA125)、糖类抗原199(CA199)及癌胚抗原(CEA)水平对比,差异无统计学意义(P>0.05);治疗后,两组CA125、CA199及CEA水平均下降,且研究组低于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)指标对比,差异无统计学意义(P>0.05);治疗后,两组患者CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)指标均有提高,且研究组高于对照组,差异有统计学意义(P<0.05)。对照组不良反应发生率为36.11%,研究组为25.00%,对比差异无统计学意义(P>0.05)。结论贝伐珠单抗靶向治疗卵巢癌患者,能有效降低患者肿瘤标志物水平,提升免疫功能,且用药安全性得以保证。
Objective To explore the effect of bevacizumab targeted therapy on tumor markers in ovarian cancer patients.Methods 72 patients with ovarian cancer were selected and divided into control group and study group by stratified sampling method,with 36 cases in each group.Patients in control group received chemotherapy with conventional chemotherapy regimen,and patients in study group were combined with bevacizumab targeted therapy on the basis of control group.The clinical efficacy of the two groups was compared.Results Before treatment,there was no significant difference in carbohydrate antigen 125(CA125),carbohydrate antigen 199(CAI 99)and carcinoembryonic antigen(CEA)levels between the two groups(P>0.05).After treatment,CA125,CAI99 and CEA levels in 2 groups were decreased,and the study group was lower than the control group,the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)indexes between 2 groups(P>0.05).After treatment,CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)indexes were increased in 2 groups,and the study group was higher than the control group,the difference was statistically significant(PV0.05).The incidence of adverse reactions was 36.11%in the control group and 25.00%in the study group,with no statistical significance(P>0.05).Conclusion Targeted treatment of bevacizumab in ovarian cancer patients can effectively reduce the level of tumor markers,improve immune function,and ensure drug safety.
作者
夏季强
Xia Jiqiang(Department of Minimally Invasive Oncology Intervention,The Second People's Hospital ofLiaoyuan City,Liaoyuan 136200,China)
出处
《实用妇科内分泌电子杂志》
2022年第24期71-73,共3页
Electronic Journal of Practical Gynecological Endocrinology
